Praxis Precision Medicines, Inc.
PRAX
Classifica tra le azioni
#2617
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the... Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Prezzo delle azioni
$260.52
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$7.27B
Variazione (1 giorno)
7.76%
Variazione (1 anno)
48.81%
Paese
US
Scambia Praxis Precision Medicines, Inc. (PRAX)
Categoria
Healthcare
Utile per Praxis Precision Medicines, Inc. (PRAX)
Utile nel Jun 2026 TTM: $-339.13M
Secondo gli ultimi rapporti finanziari di Praxis Precision Medicines, Inc., gli utili attuali della società sono $-339.13M. Nel 2023, la società ha registrato un utile di $-123.28M, un aumento rispetto a agli utili del 2022, che erano di $-214.03M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Praxis Precision Medicines, Inc. dal 2018 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $-339.13M | 85.50% |
| 2024 | $-182.82M | 48.30% |
| 2023 | $-123.28M | -42.40% |
| 2022 | $-214.03M | 28.11% |
| 2021 | $-167.06M | 170.20% |
| 2020 | $-61.83M | 73.69% |
| 2019 | $-35.60M | 34.82% |
| 2018 | $-26.40M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $5.27B | -1,655.44% |
US
|
|
| $-3.09B | 810.28% |
US
|
|
| $-4.02B | 1,084.28% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -675.20% |
NL
|
